Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Wednesday an agreement with vaccine alliance Gavi to secure 500,000 doses of the MVA-BN mpox vaccine (marketed as JYNNEOS or IMVANEX) for Africa.
The vaccines will be funded by Gavi's First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies.
Bavarian Nordic's MVA-BN vaccine received prequalification from the WHO on 13 September. Bavarian Nordic will be ready to supply the vaccines pending the signing of a supply agreement with UNICEF, Gavi's alliance partner, which will be delivering these doses.
Gavi is also working to establish a stockpile of mpox vaccines for future outbreaks and to contribute to the establishment of a sustainable vaccine manufacturing industry in Africa.
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Bavarian Nordic secures additional USD156.8m US government contract